- Research works
- 34 ▲ 654% vs 2013–17
- Citations
- 212 6.2 per fractional work
- Top-10% rate
- 21.7% record average 16.5%
- Open access
- 30% world 28%
Not ranked overall: CRISPR Therapeutics (Switzerland) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 9.8×. Every wedge is a field page.
Which keywords describe research at CRISPR Therapeutics (Switzerland)?
By fractional works in all years, weighted toward what it does more of than the world: Genome Engineering, RNA-Guided, Immunotherapy, Lymphoma, Leukemia, Cancer Immunotherapy, CAR T Cells and Chimeric Antigen Receptor.
- Silicon
- Intellectual Property
- Biotechnology
- Public Perception
- Chimeric Antigen Receptor
- Lymphoma
- Cancer Immunotherapy
- RNA-Guided
- Genome Engineering
- Immunotherapy
- Leukemia
- CAR T Cells
- Innovation
- Epidemiology
- Genetically Modified Crops
- MEMS
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 16 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 16 words, with their numbers
- Genome Engineering12▲ 613×1 topic
- RNA-Guided12▲ 613×1 topic
- Immunotherapy5▲ 21×4 topics
- Cancer Immunotherapy4▲ 91×2 topics
- Leukemia4▲ 196×2 topics
- Lymphoma4▲ 87×3 topics
- CAR T Cells4▲ 291×1 topic
- Chimeric Antigen Receptor4▲ 291×1 topic
- Innovation2▲ 6.1×4 topics
- Public Perception2▲ 49×2 topics
- Epidemiology2◆ 1.11×10 topics
- Biotechnology1▲ 38×1 topic
- Genetically Modified Crops1▲ 295×1 topic
- Intellectual Property1▲ 31×2 topics
- MEMS1▲ 86×1 topic
- Silicon1▲ 39×1 topic
Which research topics does CRISPR Therapeutics (Switzerland) publish most on?
By volume in 2022–2025: CRISPR and Genetic Engineering, CAR-T cell therapy research, Biosimilars and Bioanalytical Methods and Renal Diseases and Glomerulopathies.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 CRISPR and Genetic Engineering Molecular Biology 4 works
- 2 CAR-T cell therapy research Oncology 1 works
- 3 Biosimilars and Bioanalytical Methods Immunology 0 works
- 4 Renal Diseases and Glomerulopathies Nephrology 0 works
- 5 Endometriosis Research and Treatment Reproductive Medicine 0 works
- 6 Vasculitis and related conditions Pulmonary and Respiratory Medicine 0 works
- 7 Cell Adhesion Molecules Research Immunology and Allergy 0 works
- 8 Ureteral procedures and complications Obstetrics and Gynecology 0 works
- 9 Immune Cell Function and Interaction Immunology 0 works
- 10 Bladder and Urothelial Cancer Treatments Surgery 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has CRISPR Therapeutics (Switzerland)'s research output changed?
Output in 2018–2022 was 654% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Basel
- University of Basel
- Novartis (Switzerland)
- University Hospital of Basel
- Roche (Switzerland)
- Swiss Tropical and Public Health Institute
- Multidisciplinary Digital Publishing Institute (Switzerland)
- University Children’s Hospital Basel
- Bank for International Settlements
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.